Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in Active Psoriatic Arthritis
NCT04957550Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Aug 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in psoriatic arthritis (PsA), sponsored by Hengrui. Started Aug 2021; status: active, not recruiting.
02
Drugs
ivarmacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04957550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957550.